Further, while pembrolizumab and anti-HER2 agent combinations are used widely in other oncologic disease groups like GI malignancies, combining anti-PD1 and anti-HER2 therapies remains under active investigation in HER2+ breast cancer (including PANACEA2, KATE-23, IMpassion0504, and CCTG IND.2295). The gene discussed is ERBB2; the disease is breast carcinoma.